ResearcherInsermNo recent work listed

Laura Bourillon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2205-9196; OpenAlex author ID A5023529152. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2019: 1 paper

Papers 1

An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Co-author DOI 10.1002/ijc.32273 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christel Larbouret · 1 shared paper, 2019 · strength 0.08
- Paper An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. DOI 10.1002/ijc.32273 ↗
André Pèlegrin · 1 shared paper, 2019 · strength 0.08
- Paper An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. DOI 10.1002/ijc.32273 ↗
Pierre‐Emmanuel Colombo · 1 shared paper, 2019 · strength 0.08
- Paper An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. DOI 10.1002/ijc.32273 ↗
Thierry Chardès · 1 shared paper, 2019 · strength 0.08
- Paper An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. DOI 10.1002/ijc.32273 ↗
Charline Ogier · 1 shared paper, 2019 · strength 0.08
- Paper An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. DOI 10.1002/ijc.32273 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.